Erosive Esophagitis (EE) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2021 To 2032


 Erosive esophagitis (EE) is a common symptom of gastroesophageal reflux disease (GERD) (GERD). Without continued treatment, most patients with healed EE (approximately 80% – 90%) will relapse within 6 – 12 months. The major esophageal complications of EE include ulcer bleeding and strictures. Although death from EE is uncommon, these complications are associated with significant morbidity and mortality rates. Although there is some overlap in acid exposure among esophagitis grades, the severity of EE is related to the duration of esophageal acid exposure. Because of their ability to control esophageal acid exposure, symptoms, and esophagitis, acid-suppressive therapy with proton pump inhibitors (PPIs) is recommended as first-line therapy for GERD and EE. Esomeprazole is the S-enantiomer of the racemic PPI omeprazole, with which it shares the exact pharmacodynamic mechanism of action. Both of these PPIs block the proton pump H+/K+ adenosine triphosphatase.

 

The competitive landscape of Erosive Esophagitis (EE) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Erosive Esophagitis (EE) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Erosive Esophagitis (EE) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Erosive Esophagitis (EE) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          Vonoprazan      Phathom Pharmaceuticals, Inc.  Phase 1

2          X842    Cinclus Pharma AG       Phase 2

3          CJ-12420          HK inno.N Corporation   Phase 3

4          DWP14012       Daewoong Pharmaceutical Co. LTD.      Phase 3

5          Lafutidine          Boryung Pharmaceutical Co., Ltd           Phase 3

6          H008    Jiangsu Carephar Pharmaceutical Co., Ltd.        Phase 2

7          Z-215   Zeria Pharmaceutical     Phase 2

8          Rabeprazole     Eisai Inc.          Phase 3

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more